Published in
Ferrata Storti Foundation, Haematologica, 4(102), p. 728-735
DOI: 10.3324/haematol.2016.151894
Links
Tools
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies
Journal article published in 2016 by
Lionel Ades,
Thomas Prebet,
Aspasia Stamatoullas,
Christian Recher,
Romain Guieze,
Emmanuel Raffoux,
Krimo Bouabdallah,
Mathilde Hunault 
,
Eric Wattel,
Laure Stalnikiewicz,
Andrea Toma,
Hervé Dombret,
Marie Sebert,
Norbert Vey,
Claude Gardin
and other authors.
,
Eric Wattel,
Laure Stalnikiewicz,
Andrea Toma,
Hervé Dombret,
Marie Sebert,
Norbert Vey,
Claude Gardin
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 